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Inthepastfewyears,thediscoveryofRNA-mediatedgenesilencingmechanisms,likeRNAinterference(RNAi),hasrevolutionized
our understanding of eukaryotic gene expression. These mechanisms are activated by double-stranded RNA (dsRNA) and mediate
gene silencing either by inducing the sequence-speciﬁc degradation of complementary mRNA or by inhibiting mRNA translation.
RNAi now provides a powerful experimental tool to elucidate gene function in vitro and in vivo, thereby opening new exciting
perspectives in the ﬁelds of molecular analysis and eventually therapy of several diseases such as infections and cancer. In hematol-
ogy, numerous studies have described the successful application of RNAi to better deﬁne the role of oncogenic fusion proteins in
leukemogenesis and to explore therapeutic approaches in hematological malignancies. In this review, we highlight recent advances
and caveats relating to the application of this powerful new methodology to hematopoiesis.
Copyright © 2006 Letizia Venturini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
ThediscoveryofRNAi
In 1998 Andrew Fire and Craig Mello discovered in a se-
ries of experiments in Caenorhabditis elegans that injection
of sense or antisense RNAs led to negligible decreases of tar-
get RNA, whereas introduction of dsRNA resulted in eﬀec-
tiveandspeciﬁcdegradationofcytoplasmicmRNA.Further-
more, these silencing eﬀects of dsRNA in Ce l e g a n swere sys-
temic and heritable [1]. Later on, the sequence-speciﬁc gene
silencing capacity of dsRNA, now known as RNA interfer-
ence (RNAi), has been linked to previously described gene
silencingphenomenasuchasposttranscriptionalgenesilenc-
ing (PTGS), co-suppression in plants, and quelling in fungi
[2–7].Followingthisexcitingandfundamentaldiscovery,in-
tensestudieswereundertakenwiththepurposetodissectthe
molecular mechanism of RNAi. Indeed, in the past few years,
many details of the biogenesis of small dsRNAs have been
elucidated, and components, structure, and function of pro-
tein complexes of the RNAi machinery have been identiﬁed.
RNAihasthusemergedasanevolutionarilyhighlyconserved
and fundamental mechanism for the regulation of gene ex-
pression and has rapidly been developed into a tool to ana-
lyze gene function.
RNAimolecularpathways
The detailed molecular mechanism of RNAi has been the
subject of numerous recent reviews [8–16]. As this review
concentrates on delivery of RNAi in the hematopoietic sys-
tem and discusses its potential diagnostic and therapeutic
applications in hematology, we will only brieﬂy resume the
principalphasesofdsRNA-mediatedgenesilencingpathways
as schematically represented in Figure 1.
Two types of small noncoding dsRNA can serve as ef-
fector molecules and trigger RNAi: small interfering RNA
(siRNA) and micro RNA (miRNA). Long dsRNAs, intro-
duced experimentally into the cell or generated as intermedi-
atesduringviralinfections[17]orasaberranttranscriptsde-
rivedfrominvertedtandemrepeatsandtransposons[18],are
processedinthecytoplasmbyaribonuclease(RNase)III-like
enzymecalledDicer[19,20]intosiRNAduplexesof21–25nt
in length with 3  dinucleotide overhangs, 5 -phosphates, and
3 -hydroxyl termini [21].
With the discovery of micro RNAs (miRNAs) the impor-
tant physiological role of RNA-mediated gene silencing for
regulating gene expression during development [22], diﬀer-
entiation [23], and apoptosis [9, 24], as well as its possible
involvement in diseases like cancer, soon became manifest
(see [8, 9] for review). miRNAs constitute a large class of
endogenously expressed, highly conserved, noncoding small
RNA molecules which act as negative regulators of gene ex-
pression in a variety of organisms ranging from plants to
mammals[9].UsuallymiRNAsaretranscribedfromendoge-
nous genes by RNA polymerase II [25, 26]a sl o n gp r i m a r y
transcripts (pri-miRNAs) (see[27] forreview)possessing 5 -
caps and 3 -poly A tails [25, 28]( Figure 1). Recent studies2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic representation of RNA-mediated gene silencing pathways. miRNAs are transcribed from endogenous genes by RNA
polymerase II as long primary transcripts (pri-miRNAs). In the nucleus, Drosha, an RNase III-like enzyme, releases the characteristic stem-
loop structure of the ∼ 70bp precursor-miRNA from the primary transcript (pre-miRNA). The pre-miRNAs are then transported from the
nucleus to the cytoplasm by exportin-5, where they are processed by Dicer to generate the mature miRNA of 21–23nt in length. Similarily,
siRNA duplexes of 21–25nt in length are generated from long dsRNAs in the cytoplasm by Dicer as well. Only the antisense strand of
the mature si/miRNAs is retained in the active ribonucleoprotein eﬀector complexes (RISC or miRNP) and acts as a guide to target the
homologous mRNA. Normally, siRNAs are fully complementary and induce the cleavage and degradation of their target mRNA transcript.
In contrast, miRNAs usually bind only with partial complementarity to the 3  untranslated region (UTR) of their cognate mRNAs and
lead to translational inhibition. Depending on the cell context and the degree of complementarity between the small RNA eﬀector and the
mRNA target, both siRNA and miRNA can induce posttranscriptional gene silencing through degradation or translational inhibition. In
addition, transcriptional gene repression has been described by repeat-associated siRNA (rasiRNA). They are believed to be loaded into
RNAi-induced transcriptional gene silencing (RITS) complexes and may target homologous genomic loci. However, this mechanism is not
yet fully understood.
suggest that miRNA expression is regulated at the level of
transcription [29–31], similarly to mRNA and likely involv-
ing a similar or identical molecular machinery. The pri-
miRNAs undergo a two-step processing to give rise to the
mature miRNAs: in the nucleus, the characteristic stem-loop
structure of the precursor-miRNA (pre-miRNA) of ∼ 70bp
is released from the primary transcript by another RNase III-
likeenzymecalledDrosha[32–36].Thepre-mRNAsarethen
transported from the nucleus to the cytoplasm by exportin-
5[ 37–40], where its 2nt 3 -hydroxyl terminus is recognized
by Dicer, which generates the mature miRNA of 21–23nt
length [41–43]. Dicer thus represents the core of the RNAi
machinery where the diﬀerent RNA-mediated gene silencing
processes converge (Figure 1).
Only one strand of the mature si/miRNAs, distinguished
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[44, 45], is retained in the active ribonucleoprotein eﬀec-
tor complexes and acts as a guide to target the homologous
mRNA (Figure 1). Normally, siRNAs are fully complemen-
tary to their cognate mRNAs and guide the RNA-induced si-
lencingcomplex(RISC)[46,47]tothetargettranscripts,fol-
lowed by cleavage and degradation. A member of the Argo-
naute (Ago) family of proteins [48, 49], which contain a
small RNA-binding domain (PAZ [50]) and an RNase ac-
tivity (PIWI domain [51]), constitutes the catalytic ribonu-
clease component of RISC responsible for cleaving the tar-
get mRNA at the center of the region complementary to the
guide RNA [48, 49]. RISC is then released and the cleaved
mRNA is degraded by cellular exonucleases. Except in plants
where they have perfect homology to their targets and act
exactly as siRNAs inducing mRNA degradation [52]u p o n
integration into complexes usually referred to as miRNA-
ribonucleoproteins (miRNPs), most miRNAs bind only with
partial complementarity to the 3  untranslated region (UTR)
and lead to translational inhibition downstream of the initi-
ation step [53]. In fact, apart from the distinction based on
their biogenesis, a precise boundary between si- and miRNA
functionality cannot always be established, since both have
been shown to be capable to target mRNA for degradation
or translational inhibition, depending on the cellular context
andthedegreeofcomplementaritybetweentheRNAeﬀector
and the mRNA target [46, 54–58].
In addition to posttranscriptional gene silencing, RNAi
has also been demonstrated to induce transcriptional repres-
sion through RNA-directed DNA methylation in plants [59],
and recent studies have reported similar eﬀects even in hu-
man cells [60, 61], inducing heterochromatin formation (see
[62, 63] for review).
RNAi IN MAMMALIAN CELLS: DESIGN, DELIVERY,
AND TARGET VALIDATION
After its discovery, RNAi was rapidly employed as a power-
ful tool for large-scale reverse genetic screens in Ce l e g a n s ,
where it can be easily induced by direct injection of dsRNAs,
by feeding worms with bacteria engineered to express si-
RNAs, or simply by soaking the animals in medium contain-
ing siRNAs. Furthermore, in nematodes, RNAi acts systemi-
cally and is a long-lasting heritable event due to the presence
of RNA-dependent RNA polymerases (RdRPs) which allow
the ampliﬁcation of the trigger and the perpetuation of the
silencing process [64–66].
In mammals, however, initial eﬀorts to use RNAi for spe-
ciﬁc gene silencing encountered more diﬃculties, especially
due to the induction of nonspeciﬁc inhibition of gene ex-
pression resulting from the activation of the interferon (IFN)
response pathway by dsRNAs longer than 30bp [67]. The
discovery from Elbashir et al [68] and Caplen et al [69] that
RNA duplexes of 21nt in length, mimicking the Dicer cleav-
ageproducts,wereabletomediateeﬃcientandspeciﬁcRNAi
upontransfectionintomammaliancellswithoutelicitingthe
INF response, ﬁnally enabled loss-of-function studies of spe-
ciﬁc target genes in mammalian systems as well.
DesigningRNAieffectormolecules
To design eﬃcient siRNAs several parameters should be
considered. Although duplex RNAs of 21nt in length were
shown to be the most eﬀective RNAi triggers, recent stud-
ies suggest that 27- to 29-mers may be more active than
21-mers [70–72]. This could be due to the fact that these
dsRNAs are processed by Dicer and thus may be incorpo-
rated directly and more eﬃciently into RISC [73]. Reynolds
et al [74] conducted systematic analyses to evaluate physic-
ochemical characteristics associated with highly functional
siRNAs and set up an algorithm with several criteria which
signiﬁcantly improved selection of potent siRNAs. To com-
ply with the rules promoting asymmetric incorporation into
RISC, the base pair at the 5  end of the siRNA antisense
(guide) strand should have a lower thermodynamic stabil-
ity compared with the 3 -end [44, 45]. Accordingly, the pres-
ence of three or more A/U nucleotides at the 3 -terminus of
the sense strand was deﬁned as a criterion for siRNA func-
tionality [74]. Low G-C content (30%–52%), lack of inter-
nal inverted repeats which can form secondary structures,
and speciﬁc nucleotide preferences at positions 3 (A), 10
(U), 13 (absence of G), and 19 (A, absence of G or C) on
the sense strand also increased the probability of selecting
a potent siRNA in this study [74]. Concerning the speci-
ﬁcity of the sequence match necessary to achieve eﬃcient
gene silencing, diﬀerent groups have reported varying de-
grees of mismatch tolerance for siRNA-mediated silencing
[75–81].MismatchedsmallRNAsmaystillbecompetentand
can function like miRNAs which may bind to mRNAs with
multiple target sites in the 3 -UTR [82]. miRNA binding is
not limited to the 3 -UTR but can include the coding se-
quence of an mRNA as well [83]. These results demonstrate
the possibility of oﬀ-target eﬀects by siRNAs used for ex-
perimental or therapeutic purposes. Therefore, for preven-
tion of cross-reactive silencing, a BLAST search of poten-
tial target sequences should be performed in order to ex-
clude candidate siRNAs with some degree of homology with
other genes [74, 84]. For the eﬃcacy of gene silencing, the
overall stability of the antisense RNA/RISC-mRNA complex
is probably more important than the absolute number of
mismatches. Accordingly, base pairing at the center of the
duplex is critical, while one or two mismatches located at
the 3 -o r5  -end of the siRNA may be well tolerated [85].
Since regions which are not involved in intramolecular fold-
ing have been demonstrated to be optimal targets [86], com-
putational approaches have been reported to analyze the sec-
ondary structure and the local folding of the target mRNA.
However, all predictions based on physicochemical charac-
teristics, sequence homologies, or secondary structure can
notguaranteethegenerationofaneﬃcientsiRNA,andfunc-
tional testing is still always required. Similarly, diﬀerent si-
RNAs targeting the same gene may have diﬀerent silencing
eﬃcacies not always predictable by the parameters discussed
above. Therefore, more than one target sequence should be
tested empirically to identify the optimal small RNA for eﬃ-
cient and speciﬁc silencing of a given target mRNA.4 Journal of Biomedicine and Biotechnology
RNAideliveryinmammaliancells
RNAi in mammalian cells can be triggered by direct intro-
duction through injection, electroporation, lipid-mediated
transfection, nanoparticles, or antibody bound enzymatical-
ly generated or chemically synthesized siRNAs, among oth-
ers. Alternatively, siRNAs or small hairpin RNAs (shRNAs)
can be delivered by vector-based intracellular expression.
SyntheticsiRNA-mediatedRNAi
siRNAs can be synthesized chemically [75, 87, 88], gen-
erated enzymatically through in vitro transcription by T7
phage polymerase [89, 90], or through endonuclease di-
gestion by recombinant Dicer of in vitro transcribed long
dsRNA [91, 92]. In mammalian cells, direct delivery of siR-
NAs can only induce transient silencing due to their limited
half-life and to their dilution during cell division.
Vector-basedRNAi
Transientdownregulationofgeneexpressionmaynotbesuf-
ﬁcient for many applications, for example, for studies of pro-
teins with long half-lives in rapidly dividing cells. In order
to produce long-lasting RNAi in mammalian cells, plasmids
and viral expression vectors have been developed to drive
continuous intracellular expression of siRNA or shRNAs un-
der the control of highly active RNA polymerase III promo-
ters such as U6 or H1 [93, 94].
As represented in Figure 2, the two strands of an siRNA
can be transcribed from distinct expression units, either
cloned in tandem or in two separate vectors [95, 96], or can
result from bidirectional transcription of a single 19- to 29-
mer DNA fragment under the control of two opposite pro-
moters [97, 98]. The intracellular expression and hybridiza-
tion of the two strands gives rise to functionally active siRNA
duplexes. However, the most commonly used approach in-
volves the intracellular expression of shRNAs. They are tran-
scribed as single-stranded RNAs from an expression cassette
inserted immediately downstream of the pol III promoter,
which contains, in the following order, a 19nt sequence ho-
mologous to the target mRNA, a spacer 6 to 9 nucleotides in
length, the antisense sequence, and the RNA pol III termina-
tor signal composed of a stretch of about 6 thymidines. Af-
ter transcription, the resulting stem-loop RNA structure, like
miRNA precursors, is cleaved by Dicer to yield a function-
ally active siRNA [93, 99, 100]( Figure 2). A second genera-
tion of RNAi-delivering vectors is based on RNA pol II pro-
moters driving transcription of shRNAs incorporated into a
miRNA chimeric transcript, comprising ﬂanking sequences
optimized for Drosha/Dicer processing [100, 101].
A major advantage of vector-dependent RNAi is the us-
age of selectable markers to generate stable transfectants or
o fr e p o r t e rg e n e ss u c ha sg r e e nﬂ u o r e s c e n tp r o t e i n( G F P )
or red ﬂuorescent protein (RFP) to identify and eventually
isolate the si/shRNA expressing cells in a quantitative man-
ner.WhenusingshRNA-expressingvectors,however,itisab-
solutely necessary to conﬁrm the sequence of the shRNA ex-
pression cassette, because genetic recombination and/or in-
troduction of point mutations are very frequent and can oc-
cur in almost every step of the cloning strategy.
Finally, when the target gene to be silenced is essential
for cell survival and/or proliferation and the constitutive
knockdown of its expression is even lethal, employing in-
ducibleortissue-speciﬁcRNAicouldbeespeciallyimportant
[100].Inthelastyears,variousmethodsforinducibleexpres-
sion of shRNAs have been described. Tetracycline-inducible
[94, 102, 103] and ecdysone-inducible [104] expression sys-
tems have been reported which mediate induced and re-
versible downregulation of gene expression. However, no
standard technique for inducible RNAi has been established
so far.
Many suspension and primary cells are diﬃcult to trans-
fect eﬃciently. However, viral transduction strategies allow
stable induction of RNAi in these cells. Particularly, the ca-
pacity of lentiviruses to integrate into the genome of non-
cycling cells, such as stem cells or terminally diﬀerentiated
cells, renders lentiviral vectors much more eﬃcient than
retroviral vectors in inducing RNAi in these cells [105, 106].
Finally, transgenic technology has also been adapted for
invivodeliveredRNAiinmice.Transgenicanimalshavebeen
reported which produce siRNAs constitutively [107]o rc o n -
ditionally, in a stage- or tissue-speciﬁc manner [108], to re-
press selected target genes. Tiscornia et al [106]e ﬃciently
used a lentiviral vector system to express siRNA in preim-
plantation mouse embryos.
InvivosystemicdeliveryofsiRNAs
ChemicalmodiﬁcationsarerequiredtopotentiatesiRNAnu-
clease and thermodynamic stability in vivo without compro-
mising their eﬃcacy. Recently, several groups reported dif-
ferent approaches for systemic in vivo delivery of siRNAs.
Soutschek et al [109] described intravenous injection in mice
of chemically modiﬁed naked siRNAs coupled to a choles-
terol group chemically linked to the terminal hydroxyl group
of the sense strand to promote entry into the cells. In vivo
delivery of chemically modiﬁed siRNAs encapsulated into li-
posome particles has been recently reported by Morrisey et
al [110], and Song et al [111] described an antibody-based
delivery system which could oﬀer a possibility for systemic,
cell-type-speciﬁc siRNA delivery.
SpeciﬁcityofRNAi-inducedgenesilencing
Prior to functional analysis, monitoring the level of target
mRNA expression is necessary for siRNA target validation.
Quantitative RT-PCR is a fast and reliable method to mea-
sure target transcript levels in speciﬁc versus control siRNA-
treated cells, to ascertain that any phenotypic changes are
really due to speciﬁc gene knockdown and not to nonspe-
ciﬁceﬀectsoftheRNAistrategy.Thisissuecanbefurtherad-
dressed by verifying that the same phenotype is induced by
siRNAs homologous to diﬀerent regions of the target tran-
script. The correlation between the extent of gene silencing
and dose of the delivered si/shRNA can oﬀer some evidence
of speciﬁcity. Finally, the availability of a rescue experimentLetizia Venturini et al 5
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Figure 2: Schematic representation of vector-based RNAi. The two strands of an siRNA can be transcribed from two tandem expression
units where the expression of the sense and the antisense strands is driven separately by their own respective promoter (A), or from a
single DNA fragment under the control of two opposite promoters (B). After intracellular expression, hybridization of the two strands gives
rise to functional siRNA duplexes. shRNAs are transcribed as single-stranded RNAs from a hairpin expression cassette cloned immediately
downstream of an RNA pol III promoter containing the sense strand homologue to the target of interest followed by a 4 to 9nt spacer, the
antisense strand, and the terminator signal. After transcription the resultant stem-loop structure is cleaved by Dicer and yields a functional
siRNA (C).
able to revert the loss-of-function phenotype can ensure
RNAi speciﬁcity.
RNAi IN THE HEMATOPOIETIC SYSTEM
siRNAsandhematopoieticcells
Apart from its transient nature in mammals, the use of RNAi
in primary hematopoietic cells is limited by the diﬃculty
to deliver siRNA through conventional transfection meth-
ods. In contrast, lentiviruses have been shown to eﬃciently
transduce human hematopoietic stem and NOD/SCID re-
populating cells (HSCs and SRCs) as well as more com-
mitted colony forming progenitors [112–114] and can of-
fer a useful means for eﬀective and stable delivery of RNAi
triggers in the hematopoietic system. Lentiviral transduc-
tion was successfully employed by our group to induce RNAi
againstthecommonβ chainofthereceptorsforgranulocyte-
macrophage colony-stimulating factor (GM-CSF), inter-
leukin (IL)-3, and IL-5 in human CD34+ SRCs and colony
forming cells [115]. Similarly, Schomber et al [116]r e p o r t e d
eﬃcient and stable silencing of the p53 gene in human
cordblood-derivedCD34+ cellsthroughlentivirus-mediated
RNAi.
ApplicationofsiRNAstotargetleukemia-associated
oncogenes
Chromosomal translocations leading to the expression of
chimeric oncoproteins are frequently involved in malignant
transformationinleukemiasandlymphomas.Inthepastfew
years, RNAi technology has been used to speciﬁcally silence
theexpressionoftranslocationproducts(Table 1).Forexam-
ple, the bcr-abl oncogene resulting from the t(9;22) translo-
cation characterizes chronic myelogenous leukemia (CML)
and some variants of acute lymphoblastic leukemia (ALL).
It codes for a constitutively active cytoplasmatic tyrosine
kinase which is both necessary and suﬃcient for leukemic
transformation in several models [129–131]. Diﬀerent re-
search groups [117–120] have demonstrated the feasibility
of speciﬁc interference with the bcr-abl expression without
aﬀecting the expression of wild-type c-abl or c-bcr using
breakpoint-speciﬁc siRNAs delivered by electroporation in
bcr-abl positive hematopoietic cell lines and primary CD34+
cells from CML patients. Upon siRNA treatment, inhibi-
tion of survival and proliferation, increased sensitivity to
the abl-speciﬁc tyrosine kinase inhibitor imatinib mesylate
(STI571) [123, 132], and increased apoptosis were observed
[119, 120].6 Journal of Biomedicine and Biotechnology
Table 1: RNAi targeting hematopoietic fusion genes.
Oncogene target Disease implication Reference
BCR-ABL Chronic myeloid leukemia
[117]
[118]
[119]
[120]
[121]
[122]
AML1-MTG8 Acute myeloid leukemia [123]
TEL-PDGFβR Chronic myelomonocytic leukemia [124]
MLL-AF4 Acute lymphatic leukemia [125]
NPM1-ALK Anaplastic large-cell lymphoma [126]
[127]
FLT3-ITD Acute myeloid leukemia [128]
In a recent study, our group used lentiviral gene trans-
fer of shRNAs to trigger stable RNAi targeting the bcr-abl
oncogene [133]. Stable, but not transient, RNAi was demon-
strated to induce depletion of bcr-abl positive cells from sus-
pension cultures. This depletion, as well as the degree of bcr-
abl gene silencing, correlates with the multiplicity of lentivi-
ralinfection(MOI),thenumberoflentiviralintegrationinto
the host cell genome, and the expression level of the RFP
reporter gene: cells with lower RFP expression and fewer
lentiviral integrations could survive and were selected in sus-
pension cultures but still showed reduced bcr-abl expression,
aberrant proliferation kinetics, and enhanced sensitivity to
STI571 as compared to controls. Furthermore, in contrast to
transient RNAi [118], stable RNAi-induced silencing of bcr-
abl inhibited the colony forming capacity of primary CD34+
cells from CML patients.
Heidenreich et al [123] used siRNAs to speciﬁcally re-
press the AML1/MTG8 fusion product resulting from the
t(8;21) translocation [134] found in about 10% to 15% of
all cases of de novo AML. Electroporation of siRNAs speciﬁc
for the fusion site of the AML1/MTG8 into the Kasumi-1
t(8;21)-positive cell line speciﬁcally suppressed the expres-
sion of the fusion product, without impairing the expression
of the two respective wild-type genes. Despite the transient
character of the RNAi strategy employed, the authors de-
scribed some functional eﬀects due to the suppression of the
fusion protein such as increased myeloid diﬀerentiation and
reduced clonogenic potential upon TGFβ/vitamin D treat-
ment.
Stable retroviral delivery of shRNAs was used by Chen et
al [124] to target the fusion sequence of the TEL-PDGFβR
fusion product derived from the t(5;12) translocation, a
recurrent cytogenetic aberration associated with chronic
myelomonocytic leukemia (CMML) [135]. Stable RNAi-
mediated inhibition of TEL-PDGFβR signiﬁcantly reduced
the proliferation of TEL-PDGFβR-transformed Ba/F3 cells,
but did not restore IL-3 dependence, concordant with a
marked decrease, but not abrogation of TEL-PDGFβRe x -
pression and selection of TEL-PDGFβR expressing cells. The
authors also reported a signiﬁcantly prolonged disease la-
tency and survival of nude mice or Balb/C mice injected with
TEL-PDGFβR-transormed Ba/F3 cells coexpressing siRNA
as compared with injection of TEL-PDGFβR-transformed
cells not expressing siRNA. However, as observed in cell
culture, the expression of siRNA alone was not suﬃcient
to completely abrogate TEL-PDGFβR-induced transforma-
tion in these murine models. A synergistic eﬀect between si-
RNAs and small molecule inhibitors of tyrosine kinase ac-
tivity, such as imatinib, was also demonstrated in TEL-
PDGFβR-transformed Ba/F3 cells.
The mixed-lineage leukemia (MLL) gene is involved in
numerous translocations in a variety of leukemias [136].
Most frequently, the MLL gene is fused to the AF4 gene as
a consequence of the t(4;11) translocation [137–139], found
in acute lymphoblastic leukemia (ALL) with poor progno-
sis in infants [140]. Thomas et al [125] applied siRNAs to
silence MLL-AF4 and demonstrated decreased proliferation
and clonogenicity of t(4;11)-positive leukemic cells as well
as induction of apoptosis through caspase-3 activation and
repression of the BCL-XL anti-apoptotic gene. They also ob-
served that MLL-AF4 depletion resulted in a reduced ex-
pression of the homeotic genes HoxA9, MEIS1, and HoxA7,
known to be upregulated by MLL fusion proteins, and of the
CD133 marker for hematopoietic stem cell and early progen-
itors, which may suggest a reactivation of hematopoietic dif-
ferentiation. Finally, using a NOD/SCID mouse xenotrans-
plantation model, the authors showed that siRNA-mediated
repression of MLL-AF4 compromised leukemic engraftment
and the development of leukemia in vivo.
The t(2;5) chromosome translocation fuses the ALK
(anaplastic lymphoma kinase) gene on chromosome 2 to
the nucleophosmin (NPM1) gene on chromosome 5 and
is associated with anaplastic large-cell lymphomas (ALCLs)
[141] .I nar e c e n ts t u d y ,P i v ae ta l[ 127] reported that silenc-
ing of NPM1-ALK induced by shRNAs directed against the
3  sequences encoding the cytoplasmatic domain of ALK-R,Letizia Venturini et al 7
which is retained in all oncogenic fusion proteins involving
ALK, leads to abrogation of NPM1-ALK-mediated transfor-
mation of MEF cells and inhibition of cell growth in sev-
eral human NPM1-ALK-positive cell lines. Moreover, an in-
creased number of apoptotic cells together with caspase ac-
tivation and downregulation of the anti-apoptotic protein
survivin were detected in ALCL cells 4 days after lentivirus-
mediated RNAi. Similar results were seen in vivo: shRNA-
expressing ALCL cells injected into NOD/SCID mice re-
vealed a reduction in tumor formation as compared to con-
trol cells. Furthermore, in a second series of experiments, in-
jectionoflentivirusesdrivingshRNAexpressiondirectlyinto
ALCL tumor masses showed growth inhibition of neoplastic
cells, and histologic sections of the tumors demonstrated the
presence of large necrotic regions and, in areas with retained
viability, many apoptotic cells.
ThereceptorFMS-liketyrosinekinase3(FLT3)isthesin-
gle most frequently mutated gene in AML. It is constitutively
activated by internal tandem duplications (ITDs) within the
juxtamembrane domain or by point mutations within the
catalytic kinase domain in approximately 30% of AML pa-
tients[142,143]andappearstoconferanunfavourableprog-
nosis. RNAi-mediated silencing of FLT3 was reported by
W a l t e r se ta l[ 128]. The authors used an siRNA pool to ef-
fectively downregulate the expression of FLT3 in FLT3-ITD-
positive human leukemia cells and showed diminished phos-
phorylationofdownstreamsignallingmolecules,comprising
STAT5, MAPK, and Akt, inhibition of cell proliferation, and
induction of apoptosis. In addition, upon siRNA treatment
in these cells, they found increased sensitivity to treatment
with the FLT3 inhibitor MLN518, further demonstrating the
potential beneﬁt of such combined therapeutic approaches.
miRNAsinthehematopoieticsystem
miRNAsassociatedwithhematopoieticdifferentiation
Fine modulation of gene expression is essential for the cor-
rect realization of diﬀerentiation programs. Consistent with
this, several groups recently demonstrated the implication of
miRNAs in controlling hematopoietic diﬀerentiation.
Chen et al [23] described three miRNAs, miR-181, miR-
223, and miR-142s, which are diﬀerentially expressed in the
murine hematopoietic system, and showed that miR-181
plays a speciﬁc role in B-cell diﬀerentiation. They found
that miR-181 is normally expressed at low levels in murine
hematopoietic progenitors and becomes upregulated dur-
ing B-cell diﬀerentiation. Overexpression of miR-181 in
hematopoietic progenitors gives rise to a greater fraction of
B-lymphoid cells than in wild-type progenitors, in vitro as
well as in vivo.
In a recent publication, Felli et al [144]d e s c r i b e dm i R -
221 and miR-222 as inhibitors of normal erythropoiesis and
indicated the kit receptor mRNA as a major target of these
two miRNAs. Using microarray chip and Northern blot-
analysis, they showed that miR-221 and miR-222 are down-
regulated in erythropoietic cultures of cord blood CD34+
progenitors. In addition, they observed an impairment of
human CD34+ cell engraftment in NOD/SCID mice as well
as an inhibition of cell growth in the c-kit+ TF-1 ery-
throleukemic cell line upon overexpression of miR-221 and
miR-222.
Recent studies conducted by Fazi et al [29] revealed the
implication of miR-223 in human myeloid diﬀerentiation:
miR-223 expression increases during retinoic acid- (RA-) in-
duced granulocytic diﬀerentiation of the NB4 promyelocytic
cell line as well as of blasts from patients with acute promye-
locytic leukemia (APL) undergoing RA treatment. The au-
thors depicted a ﬁnely regulated network involving miR-223
and the transcription factors C/EBPα, well known for its im-
plicationingranulocyticdiﬀerentiation[145–147],andNFI-
A[ 148, 149]. C/EBPα and NFI-A, which can induce or re-
press miR-223 expression, respectively, are in competition
for an overlapping binding site on the miR-223 promoter. In
undiﬀerentiated cells, NFI-A maintains miR-223 and conse-
quently its translation inhibitory eﬀect at low levels. Upon
RA treatment, C/EBPα displaces NFI-A from the miR-223
promoter, thus activating its expression. Interestingly, NFI-
A is a target of miR-223 which, through a positive feedback,
represses NFI-A translation, reduces the competition with
C/EBPα, and maintains sustained levels of its own expres-
sion.
miRNAalterationsinhematologicalmalignancies
Theexpressionofaboutone-thirdofhumanmRNAsappears
toberegulatedbymiRNAs,eachofwhich,accordingtocom-
putational analysis, is predicted to regulate a broad spectrum
of diﬀerent mRNAs [150], revealing a very complex regula-
tory network. As cancers essentially derive from alteration
of gene expression and/or gene function, it is not surprising
that several recent publications supported the direct involve-
ment of miRNAs in tumorigenesis. Approximately 50 per-
cent of the known human miRNA genes are located at fragile
sitesandcancer-associatedregionsofthegenome[151].Dys-
regulation of various human miRNAs has been associated
with leukemias and lymphomas: the precursor of miR-155
was found to be overexpressed in the majority of childhood
Burkitt lymphoma [152]; the miR-15a/miR-16 cluster at lo-
cus 13q14 is frequently deleted or downregulated in patients
with B-cell chronic lymphocytic leukemia (CLL), mantle cell
lymphoma, and multiple myeloma [153]. As miR-15/16 was
demonstrated to induce apoptosis by targeting the apopto-
sis inhibitor protein BCL2 in CLL cells [154], downregula-
tion of miR-15a and miR-16-1 can contribute to malignant
transformation through BCL2 upregulation and inhibition
of apoptosis. The miR-17-92 polycistron, located at 13q31, is
ampliﬁed in human B-cell lymphomas [155]. He et al [156]
found that enforced expression of the miR-17-92 cluster can
augment the oncogenic potential of c-myc in a mouse B-cell
lymphoma model, oﬀering the ﬁrst evidence of a miRNA to
act as an oncogene. O’Donnell et al [30] further conﬁrmed
the relationship between this miR cluster and cancer. Us-
ing a lymphoma cell line with inducible c-myc expression,
they demonstrated that the miR-17 cluster is speciﬁcally and
directly upregulated by c-myc, but at least miR-17-5p and8 Journal of Biomedicine and Biotechnology
miR-20a downregulate E2F1-protein expression, a target of
c-myc which promotes cell cycle progression. These ﬁndings
reveal a feedback mechanism through which c-Myc activates
E2F1 transcription and simultaneously induces inhibition of
its translation.
Recent microarray-based studies have provided evidence
that speciﬁc alterations in human miRNA expression pro-
ﬁles are associated with speciﬁc types of cancers. Lu et al
[157] established a sensitive method to analyze the expres-
sion proﬁles of 217 miRNAs in a panel of 334 samples rep-
resenting diverse human normal tissues and corresponding
tumors. They observed a general downregulation of miRNAs
in tumors compared with normal tissues and demonstrated
that miRNA expression proﬁles correlate with the develop-
mental origins of speciﬁc cancers. Furthermore, even within
a single developmental lineage, distinct patterns of miRNA
expression seem to reﬂect the mechanism of transformation.
Indeed, clustering of miRNA proﬁles of bone marrow sam-
ples from patients with acute lymphoblastic leukemia (ALL)
showed a nonrandom distribution into three major groups
in correlation with previously characterized molecular al-
terations and phenotypic classiﬁcations (BCR-ABL-positive
and TEL-AML1-positive samples, T-cell acute lymphoblastic
leukemias, and mixed lineage leukemias). Their results sug-
gest that miRNA expression proﬁles could be more accurate
for the classiﬁcation and diagnosis of human cancers than
mRNA microarrays.
Using miRNA proﬁling, Calin et al [158] found that dif-
ferent patterns of miRNA expression distinguish CLL cells
from normal CD5+ B cells. In a recent study based on
genome-wide expression proﬁling of a large number of sam-
ples from CLL patients [159], the same group showed that
a miRNA signature is associated with the presence of other
known prognostic factors (levels of ZAP-70 expression and
the mutational status of the immunoglobulin heavy-chain
(IgVH) gene) and withdisease progression in CLL: a molecu-
lar signature composed of 13 miRNAs diﬀerentiated CLL pa-
tients with high levels of ZAP-70 expression and unmutated
IgVH frompatientswithlowZAP-70expressionandmutated
IgVH.NineofthesemiRNAsweresigniﬁcantlyoverexpressed
in the ﬁrst group of patients, associated with a poor progno-
sis. Furthermore, 9 miRNAs of the prognostic signature were
able to discriminate between patients with a short interval
from diagnosis to therapy and patients with a longer inter-
val: in the ﬁrst group, 8 of the 9 miRNAs were upregulated,
suggesting their involvement in disease progression. The au-
thors also showed some functionally relevant mutations in
miRNA genes in CLL. Some of these mutations are located
in the ﬂanking sequences of the pre-miRNA, compromising
the correct processing and expression of the mature miRNA.
CONCLUSIONSAND FUTURE PERSPECTIVES
Despite many remaining technical problems, current ad-
vances in strategies to extend genome-wide screens with
siRNA or shRNA libraries to mammalian cells [160–167]a s
well as speciﬁc gene silencing approaches may ﬁnally facili-
tate the identiﬁcation of essential genes involved in human
diseases and may identify new potential therapeutic targets.
On the other hand, disease- and stage-speciﬁc systematic
analysis of miRNA gene-expression proﬁles may help to es-
tablish new diagnostic and prognostic markers.
Employing RNAi in a therapeutic setting may still en-
counter numerous obstacles: the issue of eﬃcient delivery in
a clinical setting, as well as problems deriving from toxicity,
and possible oﬀ-target eﬀects.
While viral delivery systems are certainly of great utility
for experimental models, furtherstudies are necessary before
their possible therapeutic application may become possible
in the future.
If all these obstacles can be overcome, cancer-speciﬁc
oncogenes, such as the fusion genes produced by chromo-
s o m a lt r a n s l o c a t i o n si n v o l v e di ns e v e r a lt y p e so fl e u k e m i a ,
could be suitable candidates for tumor cell-speciﬁc target-
ing in RNAi-mediated therapeutic approaches. Beside those,
gene expression by infectious organisms may be targeted by
RNAi. Indeed, early clinical trials are under way or being
started targeting vascular epidermal growth factor (VEGF)
receptor in age-related macular degeneration or genes ex-
pressed by respiratory syncytial virus (RSV). Finally, as sug-
gested by recent reports demonstrating the cooperative ef-
fectsofRNAiandselectivemolecularinhibitors,suchasima-
tinib for Bcr-Abl [119, 120]a n dT E L - P D G F βR[ 124], and
thekinaseinhibitor MLN518forFLT3[128],combination of
targetedtherapiesincludingsmallmoleculesandRNAicould
be taken into consideration, especially when drug resistance
becomes a problem.
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